Rucaparib vs Standard-of-Care Chemotherapy for BRCA1/2-Mutated, Relapsed Ovarian Cancer

Posted: 04/21/2022 | By: Chase Doyle

Question 1 of 5

In the phase III ARIEL4 trial, median progression-free survival in the rucaparib group was how many months in the intention-to-treat population?

Choose 1